Menu Close

CAR-T Cell Therapy: Will First To Market Mean First To Disappoint?

Gilead and Novartis have launched the first two autologous CAR-T cell therapies. Combined, their first year revenues were less than $250 million. Significant manufacturing expansion plans have … (본문 전체 11/6/2018 3:49 AM)